In the Pipeline
In the Pipeline
• EntreMed has begun a Phase II clinical trial with its angiogenesis inhibitor Endostatin for the treatment of Stage IV metastatic melanoma. In February, EntreMed’s angiogenesis inhibitor received orphan drug status from the FDA.
• Millennium Pharmaceuticals has announced the initiation of a Phase I clinical trial of MLN518 in patients with acute myeloid leukemia. MLN518 is the first receptor tyrosine kinase (RTK) inhibitor of Millennium’s RTK program to enter human clinical trials.
• Cell Genesys has initiated a Phase II clinical trial of GVAX pancreatic cancer vaccine in patients with inoperable or metastatic pancreatic cancer.
• Medinox has started a Phase I clinical trial of NOX-700, an orally active nitric oxide blocking agent in development for diabetes mellitus.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.